Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Filings
57 filings of ASTERDM since November 2024; the newest 40 below.
board outcome 14, presentation 13, transcript 11, acquisition 6, credit rating 5, scheme 3
| Filed | Type | Subject | |
|---|---|---|---|
| 13 Nov 2026 | transcript Acquisition, Capex, Guidance, Results | Aster DM Quality Care Limited has informed the Exchange about TranscriptAI summaryAster DM Quality Care filed the transcript of its earnings conference call held on 6 November 2026 for the quarter and half-year ended 30 September 2026. Management (Varun Khanna, MD & Group CEO) said Q2 FY27 was the first full quarter after the merger, with record revenue of INR 2,829 crore (up 19% year-on-year), operating EBITDA of INR 678 crore (up 25%) and operating margin of 24%. Management said normalised profit after tax grew 34% year-on-year and INR 16.6 crore of synergies was realised in the quarter, with an annualised run-rate of about INR 65 crore. Management said the bed pipeline of 4,230 additional beds would take total capacity from 10,840 to over 15,000, and that over INR 1,200 crore was invested in capex over the last 18 months. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2026 | acquisition Acquisition, Capex, Legal | Aster DM Quality Care Limited has informed the Exchange about Board's approval for conversion of a pre-existing loan extended by the Company to Sri Sainatha Multispeciality Hospitals Private Limited ( Sri Saintha ), a wholly owned subsidiarAI summaryAster DM Quality Care filed the outcome of its 6 November 2026 board meeting with BSE and NSE. The board approved converting a loan of INR 102.46 Cr extended to its wholly owned subsidiary Sri Sainatha Multispeciality Hospitals Private Limited into 10,24,62,779 equity shares of face value INR 10 each, as part of internal capital restructuring, with completion expected within 3 months. The company continues to hold 100% of Sri Sainatha's equity share capital; the filing states there is no fresh infusion of funds and no change in ownership or control. The board also approved seeking shareholder approval through a postal ballot and the termination or closure, by mutual consent, of the O&M Agreement dated 4 March 2016 and the Medical Services Agreement dated 1 April 2026 with DM Education and Research Foundation, with consequent cessation of related operations. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2026 | presentation Acquisition, Results | Aster DM Quality Care Limited has informed the Exchange about Investor PresentationAI summaryRevised investor presentation for the Q2 and H1 FY27 (quarter and half-year ended 30 September 2026) earnings call, filed to correct a typographical error in the workforce number in the earlier version. Q2 FY27 revenue of INR 2,829 Cr, up 19% YoY; operating EBITDA of INR 678 Cr, up 25% YoY, with a 24.0% operating EBITDA margin (+111 bps YoY), as stated in the presentation. Normalised PAT (post NCI) of INR 281 Cr, up 34% YoY, with a 9.9% margin, per the presentation. Management said the quarter was the highest revenue, operating EBITDA and margin in the first quarter as a combined entity, following the merger. Management reported INR 16.6 Cr of synergies realised in Q2 FY27 against a full synergy potential of INR 200 Cr, with an annualised runway of INR 65 Cr. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2026 | presentation Acquisition, Results | Aster DM Quality Care Limited has informed the Exchange about Investor PresentationAI summaryAster DM Quality Care filed the management presentation for its earnings call on 6 November 2026 covering unaudited standalone and consolidated results for the quarter and half-year ended 30 September 2026. Management reported Q2 FY27 revenue of INR 2,829 Cr, up 19% YoY, and operating EBITDA of INR 678 Cr, up 25% YoY, with operating EBITDA margin of 24.0%, up 111 bps YoY. Normalised PAT (post NCI) was INR 281 Cr, up 34% YoY, with a margin of 9.9%. Management said the quarter was the highest revenue, operating EBITDA and margin in the first quarter as a combined entity following the merger. Management said INR 16.6 Cr of merger synergies were realised in Q2 FY27, against a full synergy potential of INR 200 Cr and an annualised runway of INR 65 Cr including the amount achieved. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2026 | board outcome Acquisition, Results | Aster DM Quality Care Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryAster DM Quality Care Limited filed the outcome of its board meeting held on 6 November 2026, approving unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. Standalone revenue from operations for the quarter ended 30 September 2026 was INR 1,204.21 crores, against INR 725.73 crores in the quarter ended 30 June 2026 and INR 681.81 crores in the quarter ended 30 September 2025. Standalone net profit for the quarter ended 30 September 2026 was INR 104.85 crores (total comprehensive income), against a loss of INR 14.30 crores in the quarter ended 30 June 2026 and profit of INR 104.61 crores a year earlier. Standalone revenue for the six months ended 30 September 2026 was INR 1,929.94 crores, and profit for the period was INR 91.85 crores, after exceptional items of INR 124.02 crores. The results were reviewed by statutory auditor Deloitte Haskins & Sells with an unmodified conclusion; the auditor drew attention to the amalgamation of Quality Care India Limited, effective 1 July 2026, accounted at carrying value with prior period figures not restated. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Oct 2026 | transcript Acquisition, Capex, Guidance, Results | Aster DM Quality Care Limited has informed the Exchange regarding transcript of 18th Annual General Meeting held on September 28, 2026AI summaryAster DM Quality Care Limited filed the transcript of its 18th Annual General Meeting, held through video conferencing on 28 September 2026. Management said the merger of Aster DM Healthcare Limited and Quality Care India Limited became effective on 1 July 2026, and the combined network recorded proforma revenue of Rs.9273 Crores and operating EBITDA of Rs.2013 Crores in FY2025-26, a 21.7% margin. Management said the network has more than 10,800 beds across 28 cities, with a pipeline of over 4170 additional beds and a target of more than 15,000 beds in the year ahead. The Group CFO began a review of FY2025-26 financial highlights; the transcript as filed is cut off before the rest of his remarks. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 Sep 2026 | credit rating Rating | Aster DM Quality Care Limited has informed the Exchange about revision in Credit Rating of a Material SubsidiaryAI summaryAster DM Quality Care Limited filed intimation under Regulation 30 of the Listing Regulations on a credit rating revision of KIMS Healthcare Management Limited, its material subsidiary, by ICRA Limited. Long-term fund-based cash credit (Rs. 19.00 crore) and term loan (Rs. 75.00 crore) upgraded from [ICRA]AA- to [ICRA]AA (Stable); long-term/short-term unallocated limits (Rs. 104.00 crore) upgraded to [ICRA]AA(Stable)/[ICRA]A1+. Short-term fund-based others (Rs. 12.00 crore) reaffirmed at [ICRA]A1+; all ratings removed from Rating Watch with Developing Implications. Total rated amount is Rs. 210.00 crore, unchanged. ICRA cited the completed merger of Quality Care India Limited with Aster DM Healthcare Limited as improving the parent's credit profile. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Aug 2026 | scheme Acquisition, Legal | Aster DM Quality Care Limited has informed the Exchange about Scheme of Amalgamation of KIMSHEALTH Executive Leisure Private Limited with Spiceretreat Hospitality Services Private Limited, step-down subsidiaries of the CompanyAI summaryAster DM Quality Care Limited filed that the boards of KIMSHEALTH Executive Leisure Private Limited (KEL) and Spiceretreat Hospitality Services Private Limited (SHSPL), its step-down subsidiaries, approved a Scheme of Amalgamation of KEL with SHSPL on 29 August 2026, subject to statutory and regulatory approvals. The appointed date of the Scheme is 1 April 2026. Turnover as on 31.03.2026: KEL ₹1.47 crore; SHSPL ₹77.15 crore. No cash consideration is payable; 13.4391 SHSPL equity shares of ₹10 each (fair value ₹43,400 per share) will be issued for every 1,000 KEL shares of ₹10 each (KEL fair value ₹583.3 per share). The company states the amalgamation will not change its shareholding pattern, and the transaction is exempt from related party rules under Regulation 23(5)(c). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Aug 2026 | acquisition Acquisition | Aster DM Quality Care Limited has informed the Exchange about Acquisition of Equity Shares of STS Holdings Limited by a Subsidiary of the CompanyAI summaryChemistry Intermediate Holdings Limited, a Mauritius-incorporated subsidiary of Aster DM Quality Care Limited, acquired equity shares of STS Holdings Limited, a Bangladesh-based healthcare services and training company. Acquisition: 22,727,584 equity shares, 14.21% holding, for cash consideration of USD 44,114,339 at BDT 273.45 per share (face value BDT 10). STS Holdings turnover: BDT 7,777.02 million (FY to 31 March 2024), BDT 8,902.8 million (FY to 31 March 2025), BDT 10,534.24 million (FY to 31 March 2026). The company states the acquisition is in line with the Merger Framework Agreement dated 29 November 2024 and is disclosed in the Scheme of Amalgamation approved by NCLT Hyderabad on 19 June 2026. The investment is not a related party transaction, and promoters have no interest in STS Holdings; the company describes it as a further investment. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Aug 2026 | transcript Acquisition, Capex, Guidance, Results | Aster DM Quality Care Limited has informed the Exchange about Transcript of earning conference call held for quarter ended 30 June 2026AI summaryAster DM Quality Care filed the transcript of its Q1 FY27 earnings conference call held on 5 August 2026 for the quarter ended 30 June 2026, the first call after the Aster DM Healthcare and Quality Care merger (effective 1 July 2026). Management said combined proforma revenue from operations rose 20% YoY to INR 2,597 crores, EBITDA grew 30% YoY to INR 576 crores, and EBITDA margin expanded 170 bps to 22.2%. Aster DM Healthcare standalone revenue rose 22% YoY to Rs. 1,311 Cr and Operating EBITDA rose 29% to Rs. 277 Cr; normalised PAT was approximately Rs. 125 Cr, against an exceptional expense of INR 114 Cr for merger-related costs. Management said the combined entity has a net debt of INR 1162 crore as on 30 June 2026 and plans to add over 4,170 beds over the next 3 to 4 years. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Aug 2026 | acquisition Acquisition, Legal | Aster DM Quality Care Limited has informed the Exchange about Acquisition of equity shares of United CIIGMA Institute of Medical Sciences, a subsidiary company of the Company.AI summaryAster DM Quality Care Limited's board on 5 August 2026 approved a postal ballot notice, convened its 18th Annual General Meeting for 28 September 2026 at 11:30 A.M. IST via video conferencing, and approved termination of the operations and management agreement for Aster G. Madegowda Hospital, Maddur, effective on or about 5 August 2026 or a date agreed by the parties. The hospital accounted for 0.15% of the company's revenue in the last financial year; the company cited sustained operating losses and failure to reach anticipated scale and profitability. The board also approved acquisition of equity shares of United CIIGMA Institute of Medical Sciences Private Limited, an existing subsidiary, pursuant to exercise of put option rights by certain minority shareholders under the Shareholders' Agreement; the filing states the transaction is at arm's length. The target reported turnover of Rs 153.64 crores for the financial year ended 31 March 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Aug 2026 | presentation Acquisition, Results | Aster DM Quality Care Limited has informed the Exchange about Investor PresentationAI summaryAster DM Quality Care filed the management's earnings presentation for the quarter ended 30 June 2026 (Q1 FY27), for the earnings call on 5 August 2026; figures are unaudited and indicative, subject to audit of merged accounts. The merger became effective on 1 July 2026, forming Aster DM Quality Care Limited, and management said it was executed on schedule. Proforma combined revenue from operations was INR 2,597 crore in Q1 FY27, up 20% YoY from INR 2,156 crore; management cited 13% growth in patient volumes. Proforma combined operating EBITDA was INR 576 crore, up 30% YoY, with operating EBITDA margin of 22.2%, up 170 bps; RoCE was 22.9%, up 246 bps. Proforma net debt was INR 1,673 crore as presented. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Aug 2026 | board outcome Results | Aster DM Quality Care Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryAster DM Quality Care Limited's board approved the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 at a meeting held on 5 August 2026. Standalone revenue from operations for Q1 FY27 was INR 725.73 crores, up from INR 613.04 crores in the year-ago quarter. Standalone total income was INR 764.76 crores, and the company reported a standalone net loss of INR 14.30 crores for the quarter, compared with a profit of INR 80.59 crores in the year-ago quarter. Standalone profit before exceptional items and tax was INR 120.68 crores; exceptional items were a charge of INR 109.79 crores (refer Note 7 of the filing). Basic loss per share was INR (0.28) for the quarter, not annualised. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jul 2026 | credit rating Acquisition, Rating | Aster DM Quality Care Limited has informed the Exchange about Credit RatingAI summaryCRISIL Ratings Limited has assigned long-term bank facilities a rating of Crisil AA+/Stable and short-term bank facilities a rating of Crisil A1+, both marked as assigned. Total rated amount is ₹860.50 crore. The rated facilities were novated from Quality Care India Ltd (QCIL) following its merger with the Company, effective July 1, 2026. The detailed rationale is available on the CRISIL website and on the Company's website. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Jul 2026 | credit rating Rating | Aster DM Healthcare Limited has informed the Exchange about Credit Rating- RevisionAI summaryAster DM Quality Care Limited filed intimation under Regulation 30 of a revised credit rating from ICRA Limited dated July 10, 2026. Long-term fund-based term loan rated amount raised from ₹382.00 crore to ₹1,607.00 crore; ICRA upgraded it from [ICRA]A+ to [ICRA]AA (Stable), removed it from Rating Watch with Positive Implications, and assigned it for an enhanced amount. Short-term fund-based working capital facilities (₹190.00 crore) and short-term non-fund based working capital facilities (₹30.00 crore) were reaffirmed at [ICRA]A1+. Total rated amount rose from ₹602.00 crore to ₹1,827.00 crore. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 01 Jul 2026 | board outcome Legal, Management change | Change in Board of Directors, KMP, SMP, revised ESOP Scheme and other related mattersAI summaryBoard of Aster DM Healthcare Limited (ASTERDM) met on 1 July 2026 and approved several changes, subject to shareholder approval where stated, with effect from 1 July 2026 unless noted. Appointed Mr. Varun Khanna as Additional Director and Managing Director & Group CEO for five years; appointed Mr. Neeraj Jain, Mr. Kewal Handa and Mr. V K Mathews as Independent Directors for three years each; appointed Ms. Ayshwarya Vikram and Mr. Ganesh Mani as Non-Executive Directors. Independent Directors Mr. M M Nambiar and Mr. C. J. George and Non-Executive Directors Dr. Zeba Azad Moopen and Mr. Shamsudheen Bin Mohideen Mammu Haji resigned effective 1 July 2026. Mr. Hitesh Dhaddha resigned as Chief Investor Relations and M&A Officer effective close of business on 18 July 2026; Mr. Sunil Kumar M R to take additional role of Head – Investor Relations from 19 July 2026. Board revised the list of senior management personnel, amended the ESOP Scheme 2026 (renamed Aster DM Quality Care Limited Employee Stock Option Scheme 2026, removed re-pricing provisions), and re-designated Ms. Alisha Moopen as Executive Director and Dr. Azad Moopen and Ms. Alisha Moopen as Non-Key Managerial Personnel. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jun 2026 | acquisition Acquisition | Aster DM Healthcare Limited has informed the Exchange about acquisition of Optionally Convertible Redeemable Preference Shares in an Associate CompanyAI summaryAster DM Healthcare acquired 3,57,143 Optionally Convertible Redeemable Preference Shares (OCRPS) of Rs. 10 face value in Alfaone Medicals Private Limited, an associate company, on June 29, 2026, by subscribing in its rights issue. Price per OCRPS is Rs. 700 including security premium of Rs. 690; total consideration is Rs. 25,00,00,100, paid in cash. Post-acquisition, the company holds 37,54,243 OCRPS (100% of OCRPS) and 11,50,941 equity shares (48.91%), with no change in equity holding. The transaction is a related party transaction approved by the Board, done at arm's length, and the investment is for general corporate purposes. Alfaone Medicals, incorporated December 3, 2020, trades in drugs and pharmaceuticals; turnover was Rs. 589.55 lakhs in FY2025-26, Rs. 616.32 lakhs in FY2024-25 and Rs. 621.79 lakhs in FY2023-24. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 25 Jun 2026 | board outcome Acquisition, Dividend / buy-back, Legal | Aster DM Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on June 25, 2026: noting of NCLT Order and Fixation of Record Date pursuant to the Scheme of AmalgamationAI summaryBoard of Aster DM Healthcare met on 25 June 2026 and took on record the NCLT Hyderabad Bench order dated 19 June 2026 approving the Scheme of Amalgamation of Quality Care India Limited (transferor) into Aster DM Healthcare Limited (transferee). The Board fixed 9 July 2026 as the Record Date for determining shareholders of the transferor company entitled to equity shares of the transferee company. Share exchange ratio under the Scheme: 977 equity shares of face value INR 10 each of Aster DM Healthcare for every 1000 equity shares held in Quality Care India Limited. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Jun 2026 | acquisition Acquisition, Capex | Aster DM Healthcare Limited has informed the Exchange about AcquisitionAI summaryAster DM Healthcare Limited intimated that on June 18, 2026 it acquired 4,50,89,995 equity shares of Rs. 10 each in Aster DM Super-Specialty Hospital (Sarjapur) Private Limited through a rights issue. The total cost of acquisition is Rs. 45,08,99,950 paid in cash, giving the company 100% shareholding in the entity. The entity was incorporated on July 21, 2025 in Bengaluru to set up and operate healthcare services and has not yet commenced business, so no turnover is reported. The transaction is between a holding company and its wholly owned subsidiary and is exempt from related party transaction provisions under Regulation 23(5) of the SEBI Listing Regulations; no governmental or regulatory approvals are required. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Jun 2026 | presentation Acquisition, Capex, Results | Aster DM Healthcare Limited has informed the Exchange about Investor PresentationAI summaryAster DM Healthcare filed an investor presentation on its financial performance dated June 2026 (filed June 03, 2026). As of March 31, 2026, the company reported 202 hospitals, 5,449 capacity beds, 61% occupancy and ARPOB of INR 51,800 for FY26. FY26 revenue was INR 4,643 Cr with Operating EBITDA margin of 20.4%; three-year revenue CAGR was 26% and three-year capex was ~INR 1,280 Cr. Operating EBITDA for FY26 is stated as INR 947 Cr, excluding ESOP cost of Rs. 8.3 Cr and variable O&M fee of Rs. 37.3 Cr. The presentation notes QCIL figures are indicative and subject to audit adjustments, and refers to a QCIL merger announced in 2024. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 May 2026 | transcript Acquisition, Capex, Guidance, Legal, Results | Aster DM Healthcare Limited has informed the Exchange about TranscriptAI summaryAster DM Healthcare filed the transcript of its Q4 and FY26 earnings conference call held May 1, 2026, on the audited results for the quarter and year ended March 31, 2026. Management said combined proforma (Aster plus Quality Care) Q4 revenue grew 18% year-on-year to INR 2,361 crores and Operating EBITDA rose 25% to INR 517 crores, with margin of 21.9%. Management said Aster standalone Q4 revenue was INR 1,182 crores (up 18% year-on-year) and Operating EBITDA was INR 244 crores (up 26%), with margin of 20.7%. Management said the Quality Care merger has shareholder and creditor approval (96.7% of shareholder votes in favor) and awaits final NCLT approval, with completion expected within the quarter. Management said the company plans to add nearly 2,500 beds over the coming years, taking total capacity to over 8,150 beds. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Apr 2026 | presentation Acquisition, Results | Aster DM Healthcare Limited has informed the Exchange about Investor PresentationAI summaryAster DM Healthcare filed its earnings investor presentation for the quarter and year ended March 31, 2026, for the earnings call scheduled May 1, 2026. Combined proforma (Aster + QCIL) Q4FY26 revenue was INR 2,361 crore, up 18% YoY; operating EBITDA was INR 517 crore, up 25% YoY, with margin at 21.9% versus 20.7% in Q4FY25. Combined proforma FY26 revenue was INR 9,273 crore (FY25: INR 8,105 crore), and FY26 operating EBITDA was INR 2,013 crore (FY25: INR 1,665 crore). Management said RoCE rose to 21.1% in Q4FY26 from 18.2% in Q4FY25, and the merger is expected to be completed in Q1 FY27 after 96.68% shareholder approval. QCIL numbers are indicative and subject to statutory audit adjustments; proforma figures are subject to finalisation and audit of the merged accounts. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Apr 2026 | board outcome Results | Aster DM Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryBoard of Aster DM Healthcare Limited met on April 30, 2026 and approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Statutory auditor Deloitte Haskins & Sells issued an unmodified audit report on the results. The Board meeting ran from 10:30 AM to 3:35 PM (IST). The results and auditor's report are being uploaded to the company website, www.asterdmhealthcare.in. The pages provided do not include the financial figures (revenue, profit, dividend). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Mar 2026 | dividend Dividend / buy-back | Aster DM Healthcare Limited has informed the Exchange that Board of Directors at its meeting held on March 26, 2026, declared Interim Dividend of Rs. 3 per equity share.AI summaryBoard of Aster DM Healthcare Limited, at its meeting held on March 26, 2026, declared an interim dividend of Rs. 3/- per share (face value Rs. 10/- each) for FY 2025-26. Record date for entitlement to the interim dividend is Friday, April 3, 2026. Dividend will be paid within 30 days from the date of declaration, after deducting tax at source (TDS). Shareholders are asked to submit requisite tax documents on or before April 6, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Mar 2026 | board outcome Management change | Aster DM Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on March 10, 2026.AI summaryBoard of Aster DM Healthcare approved the appointment of Dr. Azad Moopen (DIN: 00159403) as Executive Director, redesignated from Managing Director, for a term from April 15, 2026 to May 28, 2028, subject to shareholder approval by postal ballot. Dr. Azad Moopen will continue to act as Chairman of the Company. Dr. Azad Moopen founded the Company; the filing describes him as a Gold Medalist in MBBS and a post-graduate in General Medicine. Ms. Alisha Moopen (Deputy Managing Director) and Dr. Zeba Azad Moopen (Non-Executive Director) are his daughters. The filing states he is not debarred from holding the office of Director by any SEBI Order or other authority. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Feb 2026 | transcript Acquisition, Capex, Guidance, Management change, Results | Aster DM Healthcare Limited has informed the Exchange about TranscriptAI summaryAster DM Healthcare filed the transcript of its Q3 FY26 earnings conference call held February 2, 2026, for the quarter and nine months ended December 31, 2025. Management said Aster revenue from operations was INR 1,186 crore, up 13% year-on-year, with operating EBITDA of INR 224 crore (up 11%, margin 18.9%); excluding the new Kasargod hospital, revenue and operating EBITDA grew 12% and 17%. On a combined proforma basis with Quality Care (QCIL), revenue grew 15% year-on-year to INR 2,366 crore and operating EBITDA rose 22% to INR 503 crore. Management said the merger with Quality Care awaits shareholder and NCLT approval, with the shareholders' meeting expected between February 27 and March 13, 2026, and completion expected in Q1 FY27. Management described the K&M cluster as having a softer quarter due to seasonality, scheme rationalisation and clinician movements. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Feb 2026 | presentation Acquisition, Capex, Results | Aster DM Healthcare Limited has informed the Exchange about Investor PresentationAI summaryAster DM Healthcare Limited filed an investor presentation dated February 05, 2026 on its performance, with the cover page marked February 2025. Presentation shows 9MFY26 revenue of INR 3,461 Cr (9MFY25: INR 3,138 Cr) and operating EBITDA of INR 702 Cr (9MFY25: INR 613 Cr), with operating EBITDA margin of 20.3%. Operating metrics as on December 31, 2025 include 202 hospitals, 5,451 capacity beds, 61% occupancy and ARPOB of INR 51,100. Presentation states five-year revenue CAGR of 38% and five-year operating EBITDA CAGR of 20% (till FY25), with five-year capex of about INR 1,230 Cr. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jan 2026 | presentation Acquisition, Capex, Guidance, Results | Aster DM Healthcare Limited has informed the Exchange about Investor PresentationAI summaryAster DM Healthcare filed its investor presentation for the quarter and nine months ended December 31, 2025 (Q3FY26). Combined proforma entity (Aster + QCIL) revenue from operations rose 15% YoY to INR 2,366 crores; total patient volume grew 9% YoY to 1.97 Mn. Merged entity operating EBITDA rose 22% YoY to INR 503 crores, with operating EBITDA margin at 21.3% (22% excluding Kasargod). Company has filed the merger application with NCLT on December 11, 2025; shareholder meeting to be convened between February 27 and March 13, 2026 as per NCLT direction. Management stated the company plans to add 4,080+ beds in coming years, taking total bed capacity to 14,710+ beds. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jan 2026 | board outcome Acquisition, Dividend / buy-back, Legal, Results | Aster DM Healthcare Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryAster DM Healthcare filed the outcome of its board meeting held on January 30, 2026, including unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, with an unmodified limited review report from Deloitte Haskins & Sells. The board approved the Aster DM Healthcare Limited Employees Stock Option Scheme 2026 (ESOP Scheme 2026), subject to shareholder approval. The board approved conversion of a ₹129.35 Cr inter-corporate loan into 12,93,45,537 equity shares of wholly owned subsidiary Aster DM Multispecialty Hospital Private Limited, and a shareholders' agreement dated January 30, 2026 with that subsidiary; the company says ownership or control is unchanged. The board also approved loans, guarantees or securities to group companies under Section 185 of the Companies Act, 2013, and keeping statutory registers at the Bengaluru corporate office; items on ESOP, group loans and registers will go to shareholders by postal ballot. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jan 2026 | board outcome Acquisition, Capex, Dividend / buy-back, Legal, Results | Aster DM Healthcare Limited has informed the Exchange regarding Board meeting held on January 30, 2026.AI summaryAster DM Healthcare filed the outcome of its Board meeting held on January 30, 2026, including unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, with an unmodified limited review opinion from Deloitte Haskins & Sells. The Board approved the Aster DM Healthcare Limited Employees Stock Option Scheme 2026 (ESOP Scheme 2026), subject to shareholder approval. The Board approved the conversion of a ₹129.35 Cr inter-corporate loan into 12,93,45,537 equity shares of wholly owned subsidiary Aster DM Multispecialty Hospital Private Limited, as part of an internal capital restructuring, and a Shareholders' Agreement dated January 30, 2026 with the same subsidiary. The Board also approved loans, guarantees or securities to group companies under Section 185 of the Companies Act, 2013, and keeping statutory registers at the Bengaluru corporate office; the Company will seek shareholder approval for the ESOP, group-loan and register items through a Postal Ballot. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Nov 2025 | presentation Acquisition, Results | Aster DM Healthcare Limited has informed the Exchange about Investor PresentationAI summaryAster DM Healthcare filed an investor presentation dated November 2025, with data as on September 30, 2025. As at September 30, 2025 the company reported 192 hospitals, 5,199 capacity beds, 203 pharmacies and 61% occupancy for H1FY26. H1FY26 revenue was INR 2,275 Cr with operating EBITDA margin of 21%; ARPOB was INR 50,400 and ALOS 3.1 days. Q2FY26 operating EBITDA was INR 263 Cr versus INR 233 Cr in Q2FY25, and capacity beds rose to 5,199 from 4,994 in Q2FY25. The presentation also covers the QCIL merger, which the company describes as subject to finalization and audit of the merged accounts. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Nov 2025 | transcript Acquisition, Capex, Guidance, Results | Aster DM Healthcare Limited has informed the Exchange about TranscriptAI summaryAster DM Healthcare filed the transcript of its Q2 FY26 earnings conference call (held November 7, 2025) for the quarter and half year ended September 30, 2025. Management reported Q2 FY26 revenue up 10% YoY to INR 1,197 Crore and Operating EBITDA of INR 263 Crore at a 22.0% margin; Normalised PAT (post NCI) of INR 110 Crore, up 14% YoY. Management said Kerala cluster revenue hit a record INR 620 Crore in Q2 FY26, with Operating EBITDA margin at 26.8%. Management said total capex for H1 FY26 was INR 302 Crore, with cash and cash equivalents of INR 1,276 Crore and gross debt of INR 639 Crore. Management said the merger with Quality Care India Limited (QCIL) is progressing, with BSE and NSE no-objection letters received and the company to approach NCLT next. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2025 | presentation Acquisition, Capex, Results | Aster DM Healthcare Limited has informed the Exchange about Investor PresentationAI summaryAster DM Healthcare filed its Q2FY26 earnings investor presentation for the quarter and half year ended September 30, 2025. Revenue rose 10% YoY to INR 1,197 Cr; Operating EBITDA rose 13% YoY to INR 263 Cr, with Operating EBITDA margin at 22.0% vs 21.4% in Q2FY25. Normalised PAT (post-NCI) was INR 110 Cr vs INR 97 Cr in Q2FY25 (14% growth); Kerala cluster Operating EBITDA margin was 26.8%. Management said Kasargod hospital commenced operations on October 2, 2025, and bed capacity reached 5,199 as of September 30, 2025. Management reported received no-objection letters from BSE and NSE for the merger and said Kerala revenue reached a record INR 620 Cr in Q2FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2025 | board outcome Acquisition, Legal, Management change, Results | Aster DM Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025 and other business mattersAI summaryBoard of Aster DM Healthcare approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025; the statutory auditor (Deloitte Haskins & Sells) issued an unmodified review opinion. Non-Executive Director Mr. Anoop Moopen resigned with effect from close of business on November 06, 2025, citing other preoccupations and business commitments; he also ceased as member of the Nomination and Remuneration, Stakeholders' Relationship and Investment and Finance Committees. Mr. T J Wilson (Non-Executive Director) was inducted as a member of the Nomination and Remuneration Committee with effect from November 06, 2025. Board identified new registered office premises at Ameerpet, Hyderabad, Telangana, to take effect once the Regional Director (Southern Region) approves the shift from Karnataka; the company has sub-leased part of the premises from its wholly owned subsidiary. The Board deferred consideration of the proposed Aster DM Healthcare Limited Employee Stock Option Scheme – 2025 (ESOS 2025) to a subsequent meeting. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2025 | board outcome Acquisition, Legal, Management change, Results | Aster DM Healthcare Limited has informed the Exchange regarding Outcome of the Board meeting held on November 06, 2025.AI summaryBoard of Aster DM Healthcare approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025; statutory auditor Deloitte Haskins & Sells issued an unmodified review opinion. Non-Executive Director Mr. Anoop Moopen resigned with effect from close of business on November 06, 2025, citing other preoccupations and business commitments; he also ceased as member of the Nomination and Remuneration, Stakeholders' Relationship and Investment and Finance Committees. Mr. T J Wilson (Non-Executive Director) was inducted as a member of the Nomination and Remuneration Committee with effect from November 06, 2025. Board identified new registered office premises at Ameerpet, Hyderabad, Telangana, to take effect after the Regional Director's approval order for shifting the registered office from Karnataka; a sub-lease with wholly owned subsidiary Sri Sainatha Multispeciality Hospitals Private Limited was entered into. Board deferred consideration of the proposed Aster DM Healthcare Employee Stock Option Scheme 2025 (ESOS 2025) to a subsequent meeting. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Oct 2025 | scheme Acquisition, Legal | Aster DM Healthcare Limited has informed the Exchange about Scheme of ArrangementAI summaryAster DM Healthcare received no-objection letters with 'no adverse observations' from BSE and NSE on October 06, 2025 for the proposed scheme of merger of Quality Care India Limited (transferor) into Aster DM Healthcare Limited (transferee) under sections 230-232 of the Companies Act, 2013. The scheme remains subject to other statutory and regulatory approvals, including approval of shareholders and creditors of the companies involved. The exchange letters set out seven comments and 14 points, including disclosure of ongoing adjudication, recovery and enforcement proceedings, compliance with SEBI circulars, and demat-only issuance of any new equity shares. The exchange letters also require additional shareholder disclosures on promoter and public shareholding before and after the scheme, and on the valuation basis, including the company's order book and growth projections. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Oct 2025 | credit rating Rating | Aster DM Healthcare Limited has informed the Exchange about Credit Rating- RevisionAI summaryAster DM Healthcare Limited filed intimation of a revised credit rating by ICRA Limited under Regulation 30 of the SEBI Listing Regulations, dated October 03, 2025. ICRA upgraded the long-term fund-based term loan (Rs. 382 crore) to [ICRA]A+ from [ICRA]A and kept it on Rating Watch with Positive Implications. ICRA upgraded the short-term fund-based working capital facilities (Rs. 190 crore) and non-fund based working capital facilities (Rs. 30 crore) to [ICRA]A1+ from [ICRA]A1 and removed them from Rating Watch with Positive Implications. The total rated amount is Rs. 602 crore. The rating watch reflects the pending merger with Quality Care India Limited, which the company expects to complete in Q4 FY2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Sep 2025 | transcript Acquisition, Guidance, Legal, Management change, Results | Aster DM Healthcare Limited has informed the Exchange regarding Transcript of the 17th Annual General Meeting held on 4th September 2025.AI summaryAster DM Healthcare filed the transcript of its 17th Annual General Meeting, held on September 4, 2025 by video conferencing. Chairperson Alisha Moopen, chairing in the absence of Chairman Dr. Azad Moopen, said the merger with Quality Care India Limited (QCIL, backed by Blackstone) is the largest M&A in the healthcare space; the combined entity Aster DM Quality Care Limited would have 38 hospitals and 10,301 beds across 27 cities, with a planned addition of 3,800-plus beds to reach 14,200 beds. Management said FY2025 combined proforma revenue was Rs. 8,105 crores and adjusted EBITDA was Rs. 1,661 crores, an EBITDA margin of 20.5%. Management said the merger approval process has CCI approval, with the NOC from SEBI/Stock Exchanges, shareholder and NCLT approvals pending, and completion expected by Q4 of FY2026. Management said the merger is cash neutral, expected to be EPS accretive from the first full year of operations, and that procurement synergies are expected to flow from FY2027 with an EBITDA upside potential of 10% to 15% over the next few years. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Aug 2025 | transcript Acquisition, Capex, Results | Aster DM Healthcare Limited has informed the Exchange about TranscriptAI summaryAster DM Healthcare filed the transcript of its Q1 FY26 earnings conference call, held July 31, 2025, for the quarter ended June 30, 2025. Management said revenue grew 8% year-on-year to INR 1,078 crores, operating EBITDA rose 21% to INR 215 crores with margin at 20.0%, and normalised PAT rose 22% to INR 90 crores. Management said ARPOB rose 14% year-on-year, crossing INR 50,000 per bed for the first time, and total capacity stood at 5,197 beds as of June 30, 2025, with plans to add about 2,600 beds. Management said the proposed merger with Quality Care India Limited (QCIL) is subject to further regulatory approvals; the Competition Commission of India has approved it and shareholders approved the preferential share issuance. Management said cash and cash equivalents were INR 1,455 crores against gross debt of INR 643 crores. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jul 2025 | presentation Capex, Results | Aster DM Healthcare Limited has informed the Exchange about Investor PresentationAI summaryAster DM Healthcare filed its investor presentation for the quarter ended June 30, 2025 (Q1 FY26). Revenue from operations was INR 1,078 Cr, up 8% YoY from INR 1,002 Cr; Operating EBITDA was INR 215 Cr, up 21% from INR 177 Cr, with Operating EBITDA margin at 20.0% (17.7% in Q1 FY25). Normalised PAT (post-NCI) was INR 90 Cr versus INR 74 Cr in Q1 FY25; ARPOB rose 14% YoY to INR 50,200. Bed capacity stood at 5,197 as on June 30, 2025, with plans to add 2,600+ beds to reach 7,800+ beds in coming years. Management said the Kerala cluster revenue grew 5% YoY and the Karnataka & Maharashtra cluster revenue grew 13% YoY, with EBITDA improvement attributed to disciplined resource management and rationalized overhead costs. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.